⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DWTX News
Dogwood Therapeutics, Inc. Common Stock
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
globenewswire.com
DWTX
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
globenewswire.com
DWTX
Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026
globenewswire.com
DWTX
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
globenewswire.com
DWTX
Form 8-K
sec.gov
DWTX
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
globenewswire.com
DWTX